Indeed, CBX7 has been shown to repress Ink4a/Arf locus and impair p14Arf/p53- and p16Ink4a/Rb-dependent pathways in prostate cancer, human follicular lymphomas and gastric cancer [1, 2, 4, 36]. Here, TP53 is linked to follicular lymphoma.